Prime Medicine, Inc.

PRME

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001894562

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $342.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data not computable: fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Mar 3, 2026 237 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$3.67 2026-10-23; market equity $665.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 35.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(12.1%)	(6.6%)	35.6	807	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 60.7					
Twelve-month failure probability	0.46%	0.07%	83.0	248	2026-06-30
Altman Z double-prime	(9.21)	(0.33)	60.5	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	4.84x	2.94x	38.8	834	2025-12-31
Growth and financing, sleeve percentile 63.4					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 3					
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(1.7%)	2.1%	55.4	700	2025-12-31
Net share issuance, one year	37.7%	2.5%	71.3	636	2026-02-20

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 37.7%
Short runway	cash runway is 3.6 months
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(35.2%)	7.7%	21
Distance from 52-week high	(31.8%)	(31.4%)	49
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(25.1%)	(1.0%)	22
Book value to price	0.06	0.28	21
Sales to price	0.01	0.30	5
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.65)	(0.14)	21

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$47.5M
Operating cash flow, four quarters	-$156.1M
Months of runway	3.6
Days since last periodic filing	81 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$9.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$201.1M	2025-12-31	2026-03-03	10-K	26-013569
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$162.6M	2025-12-31	2026-03-03	10-K	26-013569
3	assets	us-gaap:Assets	$342.7M	2025-12-31	2026-03-03	10-K	26-013569
4	assets	us-gaap:Assets	$297.5M	2024-12-31	2026-03-03	10-K	26-013569
5	current assets	us-gaap:AssetsCurrent	$181.3M	2025-12-31	2026-03-03	10-K	26-013569
6	current liabilities	us-gaap:LiabilitiesCurrent	$37.4M	2025-12-31	2026-03-03	10-K	26-013569
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$888.4M	2025-12-31	2026-03-03	10-K	26-013569
8	operating income	us-gaap:OperatingIncomeLoss	-$208.3M	2025-12-31	2026-03-03	10-K	26-013569
9	book equity	us-gaap:StockholdersEquity	$120.9M	2025-12-31	2026-03-03	10-K	26-013569
10	liabilities	us-gaap:Liabilities	$221.9M	2025-12-31	2026-03-03	10-K	26-013569
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.6M	2025-12-31	2026-03-03	10-K	26-013569
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.0M	2024-12-31	2026-03-03	10-K	26-013569
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2022-12-31	2023-03-09	10-K	23-007266
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.5M	2025-12-31	2026-03-03	10-K	26-013569
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$122.9M	2024-12-31	2026-03-03	10-K	26-013569
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.3M	2024-12-31	2026-03-03	10-K	26-013569
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$165.4M	2023-12-31	2025-02-28	10-K	25-008884
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.7M	2023-12-31	2025-02-28	10-K	25-008884
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$131.8M	2022-12-31	2024-03-01	10-K	24-008116
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$16.1M	2022-12-31	2024-03-01	10-K	24-008116
21	assets	us-gaap:Assets	$193.9M	2023-12-31	2025-02-28	10-K	25-008884
22	assets	us-gaap:Assets	$360.3M	2022-12-31	2024-03-01	10-K	24-008116
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	180,552,179	2026-02-20	2026-03-03	10-K	26-013569
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	131,160,842	2025-02-20	2025-02-28	10-K	25-008884

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.